Mayne Pharma reports $383.7M in annual revenue
· Mayne Pharma reported fourth quarter revenue of $86.5 million alongside full year revenue of $383.7 million for fiscal year 2026.
· The company share price performance following the announcement was not detailed in the available report.
· The business strategy focuses on portfolio growth led by products like BIJUVA and NEXTSTELLIS alongside facility expansions.
Mayne Pharma (ASX:MYX) reported an unaudited fourth quarter revenue of $86.5 million alongside a full-year revenue of $383.7 million for fiscal year 2026.
This fourth quarter revenue represents a 22% decrease compared to the previous corresponding period, while full-year revenue decreased by 6%.
"The fourth quarter saw DistributeRx continue to perform strongly and well ahead of expectations, along with continued share gains across our Women's Health portfolio, led by BIJUVA and NEXTSTELLIS, leaving the business with clear commercial momentum heading into FY27," said Mayne Pharma CEO Aaron Gray.
The company stated that fourth quarter underlying EBITDA reached $4.6 million, while total cash and marketable securities stood at $80.0 million at June 30.
The company stated that the new automated Adelaide Apothecary facility lease was executed to lift capacity approximately seven-fold to over 2.5 million prescriptions per annum.
Following the announcement, the Mayne Pharma share price was unchanged at $2.42.
The company has historically focused on expanding its pharmaceutical operations and women's health portfolio through commercial product execution and distribution networks.
